Optimize Resource Allocation for Your Medical Planning Function

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Global Medical Affairs Resourcing Benchmark for Med Planning Functions”

STUDY OVERVIEW

As the strategic backbone of pharmaceutical companies, the Medical Planning Function will greatly benefit from optimized resource allocation. By ensuring effective resource utilization, biopharma organizations can improve productivity, focus on high-priority activities, manage risks, and maintain compliance.

Best Practices, LLC undertook this benchmarking research to provide insights into how top companies manage and optimize their Medical Planning resources for maximum efficiency. The study delves into the details and capabilities of Medical Planning and Operations groups, evaluating key aspects such as productivity, outsourcing, spending, and staffing in mid-sized and large biopharma organizations.

The study also outlines best practices and lessons learned from leading organizations, offering a strategic framework for others to refine their Medical Planning processes and resource management.

KEY TOPICS

Scope of Support
Productivity and Outsourced Capabilities
Medical Planning Spend and Staffing Levels
Project Management
Advantages of Outsourcing and Insourcing
Lessons Learned

KEY METRICS

Scope of Medical Planning support
Average annual volume of Medical Planning activities
Outsourced Medical Planning capabilities
Number of FTEs (full-time equivalent employees) and CWs (contract workers) dedicated to each Medical Planning activity
Project management FTEs and approach
Benefits of outsourced and insourced Medical Planning models

SAMPLE KEY FINDINGS

Scope of Medical Planning Support: Average total annual spend is $5.9 million (or ~$1 million per brand), with 34% going to outsourced activities.
Project Management: Approximately 80% of competitors source their project managers directly from Medical Affairs, including Medical Planning.

METHODOLOGY

Best Practices, LLC engaged 30 Medical leaders from 26 leading mid-cap and large biopharma organizations in this research through a benchmarking survey.

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Biotech; Consumer Products; Health Care; Clinical Research; Laboratories

Companies Profiled:
Acadia Pharmaceuticals; AbbVie; Agenus; Alexion Pharmaceuticals; Astellas; Boehringer Ingelheim; Domp�; Fidia; Gilead Sciences; Indivior; Novartis; Novo Nordisk; Organon; Pfizer; Pixacore; Protagonist Therapeutics; Prothena; Regeneron; Sandoz; Sanofi; Sobi; Takeda Pharmaceuticals; Teva Pharmaceuticals; UCB Pharma; United Therapeutics; Viatris

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at [email protected] or call David Guinn at 919-767-9179 if you have any questions.

Global Medical Affairs Resourcing Benchmark for Med Planning Functions

ID: 5808

Features:

Pages/Slides: 19

Published: 2024

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
611C7FC350981F15400258B35003AE060
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-global-medical-affairs-resourcing-benchmark-for-med-planning-functions
18
19
20172.70.130.35
21
22
23527255.sherryhk.tech
24/bestp/domrep.nsf
25DB